MedTrace Logo

Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.

NCT00584532 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2023-11-24

No results posted yet for this study

Summary

Genistein Combined Polysaccharide (GCP) may play a role as a secondary chemopreventive agent in the treatment of localized prostate cancer.

Conditions

Interventions

DRUG

Placebo

10 Placebo Capsules taken orally every day.

DRUG

GCP - Genistein Combined Polysaccharide

Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Robert Hackman, MD · University of California, Davis - Dept. of Nutrition

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2005-12-31
Completion
2007-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00584532 on ClinicalTrials.gov